Abstract

Cancer genetics seeks to understand the genetic basis of tumor development through population, cytogenetic, and molecular approaches. It examines inherited mutational occurrences, chromosome abnormalities, and gene-level modifications that are accountable for oncogenesis. Proto-oncogenes, tumor suppressor genes, and DNA repair genes are some of the main molecular elements. Cancer has come to be realized as a genetic disorder by historical events, starting from Hippocrates up to Theodor Boveri. Recent advances single-cell biology, CRISPR, and high-throughput sequencing have transformed diagnostics, prognostics, and individualized treatments. There are difficulties still, though, such as genomic heterogeneity, non-coding mutations, and ethics. The integration of genomic data into clinical management ushers in a new era for precision oncology. New technologies including single-cell biology, CRISPR-Cas9 genome editing, and high-throughput sequencing are changing cancer diagnosis, prognosis, and Finding targeted therapeutic methods in cancer. All these developments notwithstanding, there are still challenges such as intratumoral heterogeneity, non-coding mutations, and use of genomic data ethics. Incorporation of large-scale genomic profiling in clinical oncology is a paradigm-shift period for precision oncology with improved and more personalized treatment of cancer patients.

• 1.   Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular Biology of the Cell. 4th ed. New York: Garland Science; 2002. Chapter 23, Cancer.
• 2.   ScienceDirect. Cancer Genetics Internet. Amsterdam: Elsevier; cited 2025 May 11.
• 3.   Elsevier. Cancer Genetics Internet. ScienceDirect Topics. cited 2025 May 11
• 4.   Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348(10):919-932.
• 5.   Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer. 2007;7(4):233-245.
• 6.   Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
• 7.   Vogelstein B, Kinzler KW. The Genetic Basis of Human Cancer. McGraw-Hill; 2004.
• 8.   Weinberg RA. The Biology of Cancer. 2nd ed. Garland Science; 2013.
• 9.   Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971;68(4):820-823.
• 10.   Sherr CJ. Principles of tumor suppression. Cell. 2004;116(2):235-246.
• 11.   Weinberg RA. The Biology of Cancer. 2nd ed. Garland Science; 2013.
• 12.   Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature. 1997;386(6625):623–627.
• 13.   Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
• 14.   Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546–1558.
• 15.   Karpozilos A, Pavlidis N. The treatment of cancer in Greek antiquity. Eur J Cancer. 2004;40(14):2033–2040.
• 16.   PorterR. The Greatest Benefit to Mankind: A Medical History of Humanity. W.W. Norton; 1997.
• 17.   Bynum WF. The History of Medicine: A Very Short Introduction. Oxford University Press; 2008.
• 18.   Sudhakar A. History of cancer, ancient and modern treatment methods. J Cancer Sci Ther. 2009;1(2):1–4.
• 19.   Hajdu SI. A note from history: landmarks in history of cancer, part 1. Cancer. 2011;117(5):1097–1102.
• 20.   Boveri T. Zur Frage der Entstehung maligner Tumoren. Gustav Fischer Verlag; 1914.
• 21.   Balmain A. The critical roles of somatic mutations and environmental tumorpromoting agents in cancer risk. Nat Rev Cancer. 2001;1(1):33–42.
• 22.   Vogelstein B, Kinzler KW. The Genetic Basis of Human Cancer. McGraw-Hill; 2004.
• 23.   Mukherjee S. The Emperor of All Maladies: A Biography of Cancer. Scribner; 2010.
• 24.   Bailey MH et al. Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell. 2018;173(2):371–385.
• 25.   Martincorena I, Campbell PJ. Somatic mutation in cancer and normal cells. Science. 2015;349(6255):1483–1489.
• 26.   Aguirre AJ et al. Genomic copy number dictates a gene-independent cell response to CRISPR/Cas9 targeting. Cancer Discov. 2016;6(8):914–929.
• 27.   Tirosh I et al. Dissecting the multicellular ecosystem of metastatic melanoma by singlecell RNA-seq. Science. 2016;352(6282):189–196.
• 28.   Keren L et al. A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. Cell. 2019;174(6):1373–1387.e19.
• 29.   Wan JCM et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223–238.
• 30.   Popejoy AB, Fullerton SM. Genomics is failing on diversity. Nature. 2016;538(7624):161–164.

Data Sharing Statement

Funding